Abstract
Immunotherapy of squamous cell carcinoma (SCC) at an early stage of the disease increases the likelihood of success. We report a new vaccination strategy designed to prepare SCC vaccines from microgram amounts of tumor tissue, enabling the treatment of patients with minimal residual disease. The vaccine was prepared by transfer of sheared genomic DNA-fragments (25 kb) from KLN205 cells, an SCC cell line of DBA/2 mouse origin, into syngeneic bone marrow-derived mature dendritic cells (DCs). More than 90% of the transfected DCs took up DNA from the neoplasm and transferred genes were expressed as protein. The DCs expressed CD11c, CD11b, and the costimulatory molecules CD40, CD80 and CD86, characteristic of mature DCs. Syngeneic DBA/2J mice, highly susceptible to the growth of KLN205 cells, were injected intravenously (i.v.) with the transfected DCs, followed by a subcutaneous (s.c.) injection of the tumor cells. The strong immunogenic properties of the transfected cells were indicated by the finding that the survival of the tumor-bearing mice was prolonged (P<.001), relative to that of mice in various control groups. Enzyme-linked immuno spot (ELISPOT IFN-γ) assays revealed the activation of cell-mediated immunity directed toward the SCC in mice immunized with the transfected DCs. Two independent in vitro cytotoxicity assays indicated the presence of robust cell-mediated immunity directed toward the SCC in mice immunized with the transfected cells.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Herold-Mende C, Karcher J, Dyckhoff G, et al. Antitumor immunization of head and neck squamous cell carcinoma patients with a virus-modified autologous tumor cell vaccine. Adv Otorhinolaryngol. 2005;62:173–183.
Karcher J, Dyckhoff G, Beckhove P, et al. Antitumor vaccination in patients with head and neck squamous cell carcinomas with autologous virus-modified tumor cells. Cancer Res. 2004;64:8057–8061.
Hoffman TK, Bier H, Donnenberg AD, et al. p53 as an immunotherapeutic target in head and neck cancer. Adv Otorhinolaryngol. 2005;62:151–160.
Weise JB, Maune S, Gorogh T, et al. A dendritic cell based hybrid cell vaccine generated by electrofusion for immunotherapy strategies in HNSCC. Auris Nasus Larynx. 2004;31: 149–153.
Boon T, Van den Eynde B . Tumour immunology. Curr Opin in Immunol. 2003;15:129–130.
Couch M, Saunders JK, O'Malley Jr BW, et al. Genetically engineered tumor cell vaccine in a head and neck cancer model. Laryngoscope. 2003;113:552–556.
Kimura Y, Mizuno H, Satake K, et al. Effects of combined therapy with interleukin 2 and interleukin 12 gene-transfected tumor vaccine for head and neck carcinoma. Arch Otolaryngol Head Neck Surg. 2003;129:1181–1185.
Devaraj K, Gillison ML, Wu TC . Development of HPV vaccines for HPV-associated head and neck squamous cell carcinoma. Crit Rev Oral Biol Med. 2003;14:345–362.
Strome SE, Voss S, Wilcox R, et al. Strategies for antigen loading of dendritic cells to enhance the anti tumor immune response. Cancer Res. 2002;262:1884–1889.
Avigan D . Dendritic cell-tumor fusion vaccines for renal cell carcinoma. Clin Cancer Res. 2004;10:6347S–6352S.
O-Sullivan I, Ku G, Ertl HCJ, et al. A dendritic cell vaccine induces protective immunity to intracranial growth of glioma. Anticancer Res. 2002;22:613–622.
Son YI, Maillard RB, Watkins SC, et al. Dendritic cells pulsed with apoptotic squamous cell carcinoma have anti tumor effects when combined with Interleukin-2. Laryngoscope. 2001;111:1472–1478.
Ridgway D . The first 1000 dendritic cell vaccines. Cancer Invest. 2003;21:969–970.
Myers JN . The use of biological therapy in cancer of the head and neck. Curr Problems Cancer. 1999;23:106–134.
Strome SE, Chen L . Costimulation-based immunotherapy for head and neck cancer. Curr Treat Options Oncol. 2004;5:27–33.
Resser JR, Carbone DP . Immunotherapy of head and neck cancer. Curr Opin Oncol. 1998;10:226–232.
Lowy I, Pellicer A, Jackson JF, et al. Isolation of transforming DNA: cloning the hamster aprt gene. Cell. 1980;22:817–823.
Wigler M, Pellicer A, Silverstein S, et al. DNA-mediated transfer of the adenine phosphoribosyltransferase locus into mammalian cells. Proc Natl Acad Sci USA. 1979;76:1373–1376.
Hsu C, Kavathas P, Herzenberg LA . Cell surface antigens expressed on L cells transfected with whole DNA from non-expressing and expressing cells. Nature. 1984;312:68–69.
Kavathas P, Herzenberg LA . Stable transformation of mouse LM cells (a transformed fibroblast cell line) for human membrane T-cell differentiation antigens, HLA and B2 microglobulin: Selection by fluorescence-activated cell sorting. Proc Natl Acad Sci USA. 1983;80:524–528.
Son Y, Egawa S, Tatsumi T, et al. A novel bulk culture method for generating mature dendritic cells from mouse bone marrow cells. J Immunol Methods. 2002;262:145–157.
Acknowledgements
This work was supported by NIDCR Grant Number 1 RO1 DEO13970-O1A2 awarded to Dr Cohen.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
O-Sullivan, I., Ng, L., Martinez, D. et al. Immunity to squamous carcinoma in mice immunized with dendritic cells transfected with genomic DNA from squamous carcinoma cells. Cancer Gene Ther 12, 825–834 (2005). https://doi.org/10.1038/sj.cgt.7700847
Received:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.cgt.7700847